Cloroqualone is a quinazolinone-class
GABAergic and is an analogue of
methaqualone developed in the 1980s and marketed mainly in France and some other European countries. It has
sedative and
antitussive properties resulting from its agonist activity at the β subtype of the
GABAa receptor and
sigma-1 receptor, and was sold either alone or in combination with other ingredients as a
cough medicine. Cloroqualone has weaker sedative properties than methaqualone and was sold for its useful cough-suppressing effects, but was withdrawn from the French market in 1994 because of concerns about its potential for abuse and overdose.[1][2][3]